RDInvesting Provides Investors with Free In-Depth Equity Reports on ARII, PF, PRCP and ZGNXadmin
Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://www.rdinvesting.com/ and get exclusive access to our numerous stock reports and market updates.
American Railcar Industries, Inc. (NASDAQ: ARII) shares increased 2.14 percent to close at $46.70 a share Thursday. The stock traded between $45.06 and $46.73 on volume of 252,555 shares traded. Analysts at Standpoint Research have recently downgraded the company’s rating to “hold” from “buy”. Shares of American Railcar Industries have gained approximately 47.0 percent year-to-date.
Find out more about American Railcar Industries including full access to the free equity report at:
Pinnacle Foods Inc. (NYSE: PF) shares increased 3.40 percent to close at $28.29 a share Thursday. The stock traded between $27.73 and $28.44 on volume of 353,028 shares traded. Analysts at BMO Capital have recently initiated coverage on the company with an “outperform” rating and a price target of $31.00. Shares of Pinnacle Foods have gained approximately 27.0 percent year-to-date.
Find out more about Pinnacle Foods including full access to the free equity report at:
Perceptron, Inc. (NASDAQ: PRCP) shares declined 22.56 percent to close at $10.30 a share Thursday. The stock traded between $10.02 and $11.70 on volume of 681,062 shares traded. Analysts at Sidoti have recently downgraded the company’s rating to “neutral” from “buy”. Shares of Perceptron have gained approximately 75.0 percent year-to-date.
Find out more about Perceptron including full access to the free equity report at:
Zogenix, Inc. (NASDAQ: ZGNX) shares increased 5.34 percent to close at $2.86 a share Thursday. The stock traded between $2.83 and $2.96 on volume of 3.37 million shares traded. Analysts at Oppenheimer have recently upgraded the company’s rating to “outperform” from “perform”. Shares of Zogenix have gained approximately 115.0 percent year-to-date.
Find out more about Zogenix including full access to the free equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Research Driven Investing
Posted: November 15th, 2013 under ACCESSWIRE.